Home Quality Indicator Repository Use of Opioids at High Dosage in Persons Without Cancer

Use of Opioids at High Dosage in Persons Without Cancer

Identifying Attributes

Care Settings
Primary Care
Country
United States of America
Publishing Organisation
public reporting, Quality improvement (Internal to the specific organization), Quality Improvement with Benchmarking (external benchmarking to multiple organizations)
Type of Quality Indicator
Process
IOM Quality Dimension
Safety
Domain
Medications and Medication Management

Defining Attributes

Definition

The proportion (XX out of 1,000) of individuals without cancer receiving prescriptions for opioids with a daily dosage greater than 120mg morphine equivalent dose (MED) for 90 consecutive days or longer.

Numerator

Any member in the denominator with opioid prescription claims where the MED is greater than 120mg for 90 consecutive days or longer.

Denominator

Any member with two or more prescription claims for opioids filled on at least two separate days, for which the sum of the days supply is greater than or equal to 15.

Exclusions

Any member with a diagnosis for Cancer or a Prescription Drug Hierarchical Condition Category (RxHCC) 8, 9, 10, or 11 for Payment Year 2015; or RxHCC 15, 16, 17, 18, or 19 for Payment Year 2016 (see list in S.11 and S.2b); or a hospice indicator (Medicare Part D) from the enrolment database.

Use of Risk Adjustment
No
Risk Adjustments

None

Stratifications

None

Collection and Reporting Attributes

Type of Data Collection
Administrative data
Data Collection Methods

Claims data

Frequency of Data Collection
Frequency of Data Collection in Days
Reporting Methods
Reporting Frequency
Reporting Frequency in Days
Indicator Has Recommended Targets
No

Source and Reference Attributes

Evidence Source

p4qm.org/measures

Technical Specifications

p4qm.org/measures/2940

Link to Measurement Tools
Quality Indicator Confirmed to be Part of a Program Used to Monitor Quality and Safety of Care Among Older People at a Population-Level between 2012-2022
Yes
Assessed by the Australian Consortium for Aged Care Collaborators as Generally Containing Good Properties (Importance and Scientific Acceptability)
No
Australian Consortium for Aged Care Endorsed
No
Identified by PHARMA-Care Project
No
Upload Date
02 December 2025

Contents

Actions

Date Modified 02 December 2025